Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BNTC Benitec Biopharma

Closed 07-08 16:00:00 EDT

13.48

+0.04

+0.30%

盘后13.48

+0.000.00%

16:10 EDT

High13.64	Low12.95	Vol79.04K
Open13.40	D1 Closing13.44	Amplitude5.13%
Mkt Cap461.76M	Tradable Cap241.63M	Total Shares34.25M
T/O1.06M	T/O Rate0.44%	Tradable Shares17.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BNTC","market":"US","secType":"STK","nameCN":"Benitec Biopharma","latestPrice":13.48,"timestamp":1783540800000,"preClose":13.44,"halted":0,"volume":79042,"hourTrading":{"tag":"盘后","latestPrice":13.48,"preClose":13.48,"latestTime":"16:10 EDT","volume":676,"amount":9114.48,"timestamp":1783541403809,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.002976190476190545,"floatShares":17925000,"shares":34254907,"eps":-0.933773,"marketStatus":"Closed","change":0.04,"latestTime":"07-08 16:00:00 EDT","open":13.4,"high":13.64,"low":12.95,"amount":1058539,"amplitude":0.051339,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.933773,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783584000000},"marketStatusCode":5,"adr":1,"adrRate":200,"listingDate":1439870400000,"exchange":"NASDAQ","adjPreClose":13.44,"postHourTrading":{"tag":"盘后","latestPrice":13.48,"preClose":13.48,"latestTime":"16:10 EDT","volume":676,"amount":9114.48,"timestamp":1783541403809,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.640104,"impliedVol":0.2467,"impliedVolPercentile":0.1514},"requestUrl":"/m/hq/s/BNTC","defaultTab":"news","newsList":[{"id":"2649988265","title":"Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988265","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649988265?lang=en_us&edition=fundamental","pubTime":"2026-07-07 16:38","pubTimestamp":1783413535,"startTime":"0","endTime":"0","summary":"July 2 (Reuters) - NOVARTIS AG::*NOVARTIS RECEIVES EUROPEAN COMMISSION APPROVAL FOR ITVISMA FOR SPINAL MUSCULAR ATROPHY (SMA)*NOVARTIS AG - ITVISMA IS ONE-TIME FIXED DOSE GENE THERAPY FOR SMA*NOVARTIS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nRSD1xC8T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648579485","title":"Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648579485","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648579485?lang=en_us&edition=fundamental","pubTime":"2026-07-02 13:13","pubTimestamp":1782969201,"startTime":"0","endTime":"0","summary":"July 2 (Reuters) - NOVARTIS AG::*NOVARTIS RECEIVES EUROPEAN COMMISSION APPROVAL FOR ITVISMA FOR SPINAL MUSCULAR ATROPHY (SMA)*NOVARTIS AG - ITVISMA IS ONE-TIME FIXED DOSE GENE THERAPY FOR SMA*NOVARTIS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nRSD1xC8T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642428957","title":"Benitec Biopharma downgraded to Neutral from Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2642428957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642428957?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:56","pubTimestamp":1781088987,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Debjit Chattopadhyay downgraded Benitec Biopharma (BNTC) to Neutral from Buy with no price target Published first on TheFly – th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639677168","title":"Benitec Biopharma Announces Board Changes and New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2639677168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639677168?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:39","pubTimestamp":1780087158,"startTime":"0","endTime":"0","summary":"Benitec Biopharma ( ($BNTC) ) has provided an update. On May 22, 2026, Benitec Biopharma Inc.’s board appointed David Friedman as a Class III direc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/benitec-biopharma-announces-board-changes-and-new-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/benitec-biopharma-announces-board-changes-and-new-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639720616","title":"BRIEF-Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2639720616","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639720616?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:15","pubTimestamp":1780085720,"startTime":"0","endTime":"0","summary":"BRIEF-Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026May 29  - Benitec Biopharma Inc BNTC.O:BENITEC BIOPHARMA - CFO MEGAN BOSTON RESIGNS FROM BOARD EFFECTIVE MAY 22, 2026 - SEC FILINGBENITEC BIOPHARMA - MEGAN BOSTON TO CONTINUE AS CHIEF FINANCIAL OFFICER AND SECRETARY - SEC FILINGFurther company coverage: BNTC.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nFWN4261MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639672749","title":"Benitec Biopharma - Megan Boston to Continue as Chief Financial Officer and Secretary - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2639672749","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639672749?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:12","pubTimestamp":1780085536,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nFWN4261MY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639461052","title":"Benitec Biopharma files Form 3 for director David Matthew Friedman","url":"https://stock-news.laohu8.com/highlight/detail?id=2639461052","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639461052?lang=en_us&edition=fundamental","pubTime":"2026-05-29 09:09","pubTimestamp":1780016960,"startTime":"0","endTime":"0","summary":"Benitec Biopharma director David Matthew Friedman filed an initial Form 3 statement dated May 22, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLfZhb3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635051833","title":"Benitec Biopharma posts BB-301 gene therapy update for OPMD-related dysphagia","url":"https://stock-news.laohu8.com/highlight/detail?id=2635051833","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635051833?lang=en_us&edition=fundamental","pubTime":"2026-05-16 09:22","pubTimestamp":1778894567,"startTime":"0","endTime":"0","summary":"Benitec highlighted durable clinical responses to investigational gene therapy BB-301 in oculopharyngeal muscular dystrophy patients with dysphagia, citing follow-up at 12 months and 24 months in low-dose Cohort 1.All Cohort 1 study completers met company-defined responder criteria at 12 months in Phase 1b/2a open-label dose-escalation study.Interim data from first patient in higher-dose Cohort 2 at 3 months indicated responder status, with improved depth of response versus Cohort 1 in a preliminary comparison.Program update reiterated no treatment-related severe adverse events reported to date, with FDA Fast Track designation and Orphan Drug designation from FDA and EMA.Benitec positioned BB-301 as only clinical-stage therapy in development designed to treat OPMD-related dysphagia, targeting roughly 15,000 patients across North America, Europe, and Israel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260516:nNDLbxx1rh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088868","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088868?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.,·H World ADR                                     1Q       .45       BMO. ,·RBC Bearings                                     4Q      3.33   8:00 AM. ,·Compugen Ltd.                                   1Q      (.07)  7:00 AM. ,·iQIYI ADR                                         1Q      (.03)  5:00 AM. ,·Modiv Ind Cl C                                   1Q       .01. ,·8x8 Inc.                                        4Q       .08   4:05 PM. ,·Amer Sports                                       1Q       .31   6:00 AM. ,·Bilibili Spon                                   1Q       .17   6:00 AM. ,·Canaan Spon ADR                                  1Q      (.03)      BMO. ,·CAVA Grp                                        1Q       .17   4:10 PM. ,·Ceragon Net                                     1Q       .01   7:00 AM. ,·Eagle Materials                     ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DOMO","GCO","BLTE","HLNE","CAN","CGEN","DECK","FLO","HAS","BIDU","ADI","DAVA","ENS","BORR","CRVO","ALMS","BTM","ECC","GCTS","IQ","EARN","HSAI","CAVA","EDRY","FATN","AAP","DE","CPRT","ELF","INTU","CRNT","BULL","GDS","EGHT","GLNG","BZ","BNTC","BURL","CDLR","EXP","HD","AS","HTHT","CAE","BBW","BEKE","BILI","CMBT","AGYS","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635877642","title":"Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia","url":"https://stock-news.laohu8.com/highlight/detail?id=2635877642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635877642?lang=en_us&edition=fundamental","pubTime":"2026-05-15 10:55","pubTimestamp":1778813714,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating on May 12. Ritu Baral has given his Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/benitec-biopharma-reaffirmed-at-buy-on-strong-cash-runway-and-clear-bb-301-pivotal-path-in-opmd-dysphagia-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/benitec-biopharma-reaffirmed-at-buy-on-strong-cash-runway-and-clear-bb-301-pivotal-path-in-opmd-dysphagia-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","BNTC","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745692","title":"Benitec Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745692","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635745692?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:21","pubTimestamp":1778768509,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc reports results for the quarter ended March 31 - Earnings SummaryBenitec Biopharma Inc BNTC.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended Marc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R1NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717782","title":"Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717782","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717782?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:41","pubTimestamp":1778762517,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52557945/benitec-biopharma-q3-eps-0-24-beats-0-27-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635439712","title":"Benitec Biopharma Q3 net loss narrows as expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635439712","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635439712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:10","pubTimestamp":1778760636,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Q3 net loss narrows as expenses fallOverviewUS gene therapy firm's fiscal Q3 net loss narrowed from prior year as expenses fellR&D and G&A expenses declined yr/yr as BB-301 clinical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0L2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635839712","title":"Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635839712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635839712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1WV3K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712485","title":"Benitec Biopharma Inc - Cash and Cash Equivalents $184.8 Mln as of March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712485?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX285204:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712451","title":"Benitec Biopharma Inc - on Track to Engage With FDA Mid-Year to Formalize Bb-301 Pivotal Study Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712451?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX285204:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635128807","title":"Benitec Biopharma Q3 Operating Income USD -13.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635128807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635128807?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX285204:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635024522","title":"Benitec Biopharma initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2635024522","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635024522?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:53","pubTimestamp":1778601195,"startTime":"0","endTime":"0","summary":"Evercore ISI initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $25 price target BB-301 represents “an exciting opportuni...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634058243","title":"Benitec Biopharma Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634058243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634058243?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:34","pubTimestamp":1778600040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BNTC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 11:34 ET (15:34 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633468486","title":"Benitec Biopharma Inc  expected to post a loss of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633468486","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633468486?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:46","pubTimestamp":1778255180,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc  expected to post a loss of27cents a share - Earnings Preview Benitec Biopharma Inc BNTC.OQ BNTC.O is expected to  show no change in quarterly revenue when it reports  results on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1XU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.benitec.com","stockEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":0.2739},{"period":"3month","weight":0.2152},{"period":"6month","weight":0.1034},{"period":"1year","weight":-0.0037},{"period":"ytd","weight":-0.0022}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.034036},{"month":2,"riseRate":0.545455,"avgChangeRate":0.090462},{"month":3,"riseRate":0.727273,"avgChangeRate":0.04636},{"month":4,"riseRate":0.454545,"avgChangeRate":0.035631},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.04959},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.105281},{"month":7,"riseRate":0.545455,"avgChangeRate":0.056241},{"month":8,"riseRate":0.4,"avgChangeRate":-0.00465},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.108578},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.026473},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.075117},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.032403}],"exchange":"NASDAQ","name":"Benitec Biopharma","nameEN":"Benitec Biopharma","securityTypeName":"DR","adrRate":"1:200"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Benitec Biopharma,BNTC,Benitec Biopharma股票,Benitec Biopharma股票老虎,Benitec Biopharma股票老虎国际,Benitec Biopharma行情,Benitec Biopharma股票行情,Benitec Biopharma股价,Benitec Biopharma股市,Benitec Biopharma股票价格,Benitec Biopharma股票交易,Benitec Biopharma股票购买,Benitec Biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}